Trial Profile
Tailored Treatment of Hepatitis C Genotype 1.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2013
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TTG1
- 06 Nov 2012 Planned number of patients added (100) as reported by European Clinical Trials Database record.
- 24 Jul 2012 Additional lead trial centre (Vastra Gotalandsregionen) added as reported by European Clinical Trials Database record.
- 06 Jun 2009 New trial record